Surrozen (NASDAQ:SRZN) Upgraded by Lifesci Capital to Strong-Buy Rating

Surrozen (NASDAQ:SRZN) was upgraded by analysts at Lifesci Capital to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.50.

Surrozen Trading Down 6.3%

NASDAQ:SRZN opened at $12.12 on Thursday. Surrozen has a 12 month low of $5.90 and a 12 month high of $18.17. The company has a 50-day moving average price of $12.79 and a 200-day moving average price of $10.57. The stock has a market cap of $103.87 million, a price-to-earnings ratio of -0.54 and a beta of 0.64.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The company had revenue of $0.98 million during the quarter. Equities analysts forecast that Surrozen will post -8.49 EPS for the current fiscal year.

Institutional Trading of Surrozen

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after buying an additional 5,702 shares in the last quarter. Heights Capital Management Inc. bought a new stake in shares of Surrozen in the first quarter worth approximately $524,000. Armistice Capital LLC bought a new position in Surrozen during the second quarter valued at approximately $536,000. Adage Capital Partners GP L.L.C. grew its position in Surrozen by 37.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company’s stock worth $1,034,000 after purchasing an additional 24,000 shares during the period. Finally, Braidwell LP bought a new position in shares of Surrozen during the 2nd quarter valued at $1,252,000. 66.57% of the stock is currently owned by institutional investors.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.